Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

Novartis Gets Spark Therapeutics' Luxterna License Outside US

by Zacks Equity Research

Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.

    Zacks Equity Research

    Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

    by Zacks Equity Research

    J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

      Zacks Equity Research

      Will Pfizer (PFE) Surpass Estimates This Earnings Season?

      by Zacks Equity Research

      While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.

        Zacks Equity Research

        Why AbbVie (ABBV) Might Surprise This Earnings Season

        by Zacks Equity Research

        AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

          Zacks Equity Research

          Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?

          by Zacks Equity Research

          Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.

            Zacks Equity Research

            Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto

            by Zacks Equity Research

            Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.

              Zacks Equity Research

              The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

              by Zacks Equity Research

              The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                Zacks Equity Research

                Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

                by Zacks Equity Research

                Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.

                  Zacks Equity Research

                  Novartis Announces Positive Results on Migraine Candidate

                  by Zacks Equity Research

                  Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,

                    Zacks Equity Research

                    3 Large Cap Pharma Stocks to Beat Earnings This Quarter

                    by Zacks Equity Research

                    The fourth-quarter outlook for Pharma stocks looks bright.

                      Zacks Equity Research

                      J&J (JNJ) Q4 Earnings Top, Pharma Sales Continue to Improve

                      by Zacks Equity Research

                      J&J (JNJ) beat estimates for earnings while missing the same for sales in the fourth-quarter. It issued a mixed outlook for 2018.

                        Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck

                          Zacks Equity Research

                          What's in the Cards for Varian Medical (VAR) in Q1 Earnings?

                          by Zacks Equity Research

                          Varian Medical's (VAR) lackluster performance in Halcyon platform and disappointing financials are likely to dampen results in Q1.

                            Zacks Equity Research

                            What's in the Cards for Novartis (NVS) This Earnings Season?

                            by Zacks Equity Research

                            Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.

                              Arpita Dutt headshot

                              Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?

                              by Arpita Dutt

                              Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.

                                Zacks Equity Research

                                Amgen/Allergan's Avastin Biosimilar Secures EU Approval

                                by Zacks Equity Research

                                Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.

                                  Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

                                  by Zacks Equity Research

                                  The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis

                                    Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group

                                    by Zacks Equity Research

                                    The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group

                                      Zacks Equity Research

                                      Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?

                                      by Zacks Equity Research

                                      We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.

                                        Zacks Equity Research

                                        J&J (JNJ) Hits New 52-Week High: What's Driving the Stock?

                                        by Zacks Equity Research

                                        Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.

                                          Zacks Equity Research

                                          Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

                                          by Zacks Equity Research

                                          Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.

                                            Zacks Equity Research

                                            Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

                                            by Zacks Equity Research

                                            Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.

                                              Arpita Dutt headshot

                                              Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

                                              by Arpita Dutt

                                              Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

                                                Zacks Equity Research

                                                AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

                                                by Zacks Equity Research

                                                AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

                                                  Zacks Equity Research

                                                  4 Best Marijuana Stocks to Play the Green Rush

                                                  by Zacks Equity Research

                                                  Given the increasing bullish environment, the movement to legalize marijuana has definitely picked up steam. Below are four cannabis-linked stocks that are poised to benefit from legalization.